{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:04:23Z","timestamp":1773763463526,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jaip.2021.01.037","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:21:47Z","timestamp":1612527707000},"page":"1501-1507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate"],"prefix":"10.1016","volume":"9","author":[{"given":"Pia-Charlotte","family":"Stadler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen D.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Milner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.01.037_bib1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib2","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.01.037_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1398-9995.2000.00115.x","article-title":"Atopic dermatitis: from the genes to skin lesions","volume":"55","author":"Wollenberg","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.01.037_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2012.12.668","article-title":"The multifunctional role of filaggrin in allergic skin disease","volume":"131","author":"McAleer","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2011.06387.x","article-title":"Hyper-IgE syndrome update","volume":"1250","author":"Sowerwine","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaip.2021.01.037_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/imcb.12209","article-title":"Hyper IgE syndromes: clinical and molecular characteristics","volume":"97","author":"Al-Shaikhly","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaip.2021.01.037_bib7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/jdv.16090","article-title":"Recurrent eczema herpeticum\u2014a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients","volume":"34","author":"Seegraber","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.01.037_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2003.07.001","article-title":"Viral infections in atopic dermatitis: pathogenic aspects and clinical management","volume":"112","author":"Wollenberg","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/iub.1405","article-title":"New insights into T cells and their signature cytokines in atopic dermatitis","volume":"67","author":"Wang","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jaip.2021.01.037_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jaci.2005.12.1345","article-title":"Cathelicidin deficiency predisposes to eczema herpeticum","volume":"117","author":"Howell","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0140-6736(66)90119-X","article-title":"Job's syndrome. Recurrent, \"cold,\" staphylococcal abscesses","volume":"1","author":"Davis","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.01.037_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1542\/peds.49.1.59","article-title":"Extreme hyperimmunoglobulinemia E and undue susceptibility to infection","volume":"49","author":"Buckley","year":"1972","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2021.01.037_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2008.01.005","article-title":"The hyper-IgE syndromes","volume":"28","author":"Freeman","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.01.037_bib14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMc076367","article-title":"STAT3 mutation in the original patient with Job's syndrome","volume":"357","author":"Renner","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2021.01.037_bib16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3324\/haematol.2018.194233","article-title":"Selective loss of function variants in IL6ST cause hyper-IgE syndrome with distinct impairments of T-cell phenotype and function","volume":"104","author":"Shahin","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2021.01.037_bib18","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1084\/jem.20161810","article-title":"A\u00a0biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis","volume":"214","author":"Schwerd","year":"2017","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib19","doi-asserted-by":"crossref","first-page":"eaat4941","DOI":"10.1126\/sciimmunol.aat4941","article-title":"ZNF341 controls STAT3 expression and thereby immunocompetence","volume":"3","author":"Frey-Jakobs","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib20","doi-asserted-by":"crossref","first-page":"eaat4956","DOI":"10.1126\/sciimmunol.aat4956","article-title":"A\u00a0recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity","volume":"3","author":"Beziat","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib21","doi-asserted-by":"crossref","first-page":"e20191804","DOI":"10.1084\/jem.20191804","article-title":"Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome","volume":"217","author":"Beziat","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMe078197","article-title":"STAT3 signaling and the hyper-IgE syndrome","volume":"357","author":"Levy","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/pai.12512","article-title":"Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children","volume":"27","author":"Hagl","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jaci.2010.06.029","article-title":"Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis","volume":"126","author":"Schimke","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/all.12416","article-title":"Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern","volume":"69","author":"Boos","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.01.037_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-3476(03)00449-9","article-title":"Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity","volume":"144","author":"Renner","year":"2004","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2021.01.037_bib27","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1056\/NEJMoa0905506","article-title":"Combined immunodeficiency associated with DOCK8 mutations","volume":"361","author":"Zhang","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaci.2016.09.061","article-title":"Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency","volume":"140","author":"Kuijpers","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib29","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jaci.2014.02.025","article-title":"Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels","volume":"133","author":"Sassi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ng.3898","article-title":"Germline hypomorphic CARD11 mutations in severe atopic disease","volume":"49","author":"Ma","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2021.01.037_bib31","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaci.2014.02.013","article-title":"Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment","volume":"133","author":"Zhang","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib32","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jpeds.2012.01.056","article-title":"A\u00a0patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome","volume":"160","author":"Kilic","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2021.01.037_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2021.01.037_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2007.05.007","article-title":"The hyper IgE syndrome and mutations in TYK2","volume":"26","author":"Woellner","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2021.01.037_bib35","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jaci.2008.09.027","article-title":"Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity","volume":"122","author":"Gambineri","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib37","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2008.09.037","article-title":"Omenn syndrome: inflammation in leaky severe combined immunodeficiency","volume":"122","author":"Villa","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(03)14632-6","article-title":"Role of TBX1 in human del22q11.2 syndrome","volume":"362","author":"Yagi","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.01.037_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1442-200X.2012.03722.x","article-title":"Clinical and immunophenotypic features of atypical complete DiGeorge syndrome","volume":"55","author":"Vu","year":"2013","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jaip.2021.01.037_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archderm.1964.01590250052010","article-title":"Netherton's disease: Trichorrhexis invaginata (bamboo hair), congenital ichthyosiform erythroderma and the atopic diathesis. A histopathologic study","volume":"89","author":"Wilkinson","year":"1964","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Comel-Netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjd.13247","article-title":"Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies","volume":"172","author":"Has","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib43","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jaci.2015.05.002","article-title":"Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin","volume":"136","author":"McAleer","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1743","article-title":"Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris","volume":"38","author":"Smith","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2021.01.037_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s15006-017-0330-y","article-title":"Atopic eczema in childhood or primary immunodeficiency\u2014what needs to be considered? [in German]","volume":"159","author":"Wollenberg","year":"2017","journal-title":"MMW Fortschr Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2006.02.005","article-title":"The Wiskott-Aldrich syndrome","volume":"117","author":"Ochs","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00439-020-02141-7","article-title":"Human inborn errors of immunity underlying superficial or invasive candidiasis","volume":"139","author":"Puel","year":"2020","journal-title":"Hum Genet"},{"key":"10.1016\/j.jaip.2021.01.037_bib48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10875-012-9769-x","article-title":"Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients","volume":"33","author":"Alsum","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib50","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","article-title":"A\u00a0multiinstitutional survey of the Wiskott-Aldrich syndrome","volume":"125","author":"Sullivan","year":"1994","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2021.01.037_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaci.2015.11.024","article-title":"Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis","volume":"138","author":"Hox","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib52","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jaci.2013.08.045","article-title":"Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation","volume":"132","author":"Siegel","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1086\/302547","article-title":"Genetic linkage of hyper-IgE syndrome to chromosome 4","volume":"65","author":"Grimbacher","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaip.2021.01.037_bib54","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2009.10.038","article-title":"Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome","volume":"124","author":"Engelhardt","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib55","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.01.037_bib56","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.01.037_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.iac.2010.06.005","article-title":"Evolution of conventional therapy in atopic dermatitis","volume":"30","author":"Wollenberg","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.01.037_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib59","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib60","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib62","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.01.037_bib64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomised monotherapy phase 3 trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.01.037_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s10875-020-00751-4","article-title":"Efficacy of dupilumab for controlling severe atopic dermatitis in a patient with hyper-IgE syndrome","volume":"40","author":"Levy","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib68","author":"Frommherz"},{"key":"10.1016\/j.jaip.2021.01.037_bib69","doi-asserted-by":"crossref","first-page":"108452","DOI":"10.1016\/j.clim.2020.108452","article-title":"Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome","volume":"215","author":"Sogkas","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib70","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/all.13753","article-title":"Lung disease in STAT3 hyper-IgE syndrome requires intense therapy","volume":"74","author":"Kroner","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.01.037_bib71","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1111\/all.14197","article-title":"Comel-Netherton syndrome: a local skin barrier defect in the absence of an underlying systemic immunodeficiency","volume":"75","author":"Stuvel","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.01.037_bib72","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/1346-8138.14925","article-title":"Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin","volume":"46","author":"Liang","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.01.037_bib73","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajhg.2014.05.007","article-title":"PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia","volume":"95","author":"Stray-Pedersen","year":"2014","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaip.2021.01.037_bib75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-014-0126-0","article-title":"DOCK8 deficiency: clinical and immunological phenotype and treatment options\u2014a review of 136 patients","volume":"35","author":"Aydin","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.01.037_bib76","series-title":"DiGeorge Syndrome","author":"Lackey","year":"2020"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:27:45Z","timestamp":1761974865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2213219821001653"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.01.037","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}